Specify a stock or a cryptocurrency in the search bar to get a summary
Kezar Life Sciences Inc
KZRKezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. Address: 4000 Shoreline Court, South San Francisco, CA, United States, 94080
Analytics
WallStreet Target Price
25 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures KZR
Dividend Analytics KZR
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History KZR
Stock Valuation KZR
Financials KZR
Results | 2019 | Dynamics |